BioAtla Files 8-K for Regulation FD Disclosure, Exhibits

Ticker: BCAB · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1826892

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, disclosure, administrative

TL;DR

**BioAtla just filed an 8-K for general disclosure, keep an eye out for details.**

AI Summary

BioAtla, Inc. filed an 8-K on January 9, 2024, to disclose information under Regulation FD and to include financial statements and exhibits. This filing, under SEC File Number 001-39787, indicates that the company is providing current information to the public, which is important for investors as it ensures transparency and access to the latest developments, potentially influencing stock valuation.

Why It Matters

This filing ensures BioAtla, Inc. is transparent with investors by publicly disclosing information, which can impact investor confidence and stock price.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not inherently indicate a specific financial or operational risk.

Analyst Insight

A smart investor would review the specific content of the Regulation FD disclosure and any attached exhibits to understand the new information BioAtla, Inc. is making public, as this could contain material information not previously available.

Key Players & Entities

FAQ

What is the purpose of BioAtla, Inc.'s 8-K filing on January 9, 2024?

BioAtla, Inc. filed this 8-K to satisfy disclosure requirements under Regulation FD and to furnish financial statements and exhibits, as indicated in the 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits' sections.

What is BioAtla, Inc.'s trading symbol and where is its common stock registered?

BioAtla, Inc.'s trading symbol is BCAB, and its Common Stock, with a $0.0001 par value per share, is registered on the Nasdaq Global Market, as stated under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the business address and phone number of BioAtla, Inc. as listed in the filing?

The business address for BioAtla, Inc. is 11085 Torreyana Road, San Diego, California, 92121, and its telephone number is 858-558-0708, according to the 'BUSINESS ADDRESS' section.

Is BioAtla, Inc. considered an emerging growth company according to this filing?

No, BioAtla, Inc. is not indicated as an emerging growth company, as the checkbox for 'Emerging growth company' is marked with a '☐' (unchecked) in the filing.

What is the Central Index Key (CIK) for BioAtla, Inc.?

The Central Index Key (CIK) for BioAtla, Inc. is 0001826892, as listed under 'COMPANY DATA: CENTRAL INDEX KEY'.

Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-01-09 09:01:12

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 9, 2024, BioAtla, Inc. updated its corporate presentation (the "Corporate Presentation"), which it intends to use at various meetings with investors, investment banks and investment bank analysts, including at meetings at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The Corporate Presentation is attached hereto as Exhibit 99.1. The information set forth in Item 7.01 of this Current Report on Form 8-K ("Current Report"), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information set forth in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.

01 Financials Statements and Exhibits

Item 9.01 Financials Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 BioAtla, Inc. Corporate Presentation, dated January 2024. 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioAtla, Inc. Date: January 9, 2024 By: /s/ Richard Waldron Richard Waldron Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing